{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268401","form_type":"8-K","ticker":null,"cik":"0001874495","company_name":"Forbion European Acquisition Corp.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.232353+00:00","generated_at":"2026-06-09T01:04:12.234393+00:00","sec_items":["1.01","1.02","2.01","3.01","3.03","5.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Forbion European Acquisition Corp. completes business combination with enGene; combined entity trades as ENGN","bullets":["Business combination closed Oct 31, 2023; enGene becomes subsidiary of new public company enGene Holdings Inc.","Gross proceeds of ~$138M from trust ($25M) and PIPE ($113M); 10.4M FEAC shares redeemed.","Lead therapy EG-70 (detalimogene voraplasmid) in pivotal Phase 2 for BCG-unresponsive NMIBC; interim results expected mid-2024.","enGene management led by CEO Jason Hanson continues at helm; prior FEAC directors and officers resigned.","New enGene ordinary shares and warrants trade on Nasdaq under ENGN and ENGNW as of Nov 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268401","json":"https://secwatch.observer/filing/0001193125-23-268401.json","markdown":"https://secwatch.observer/filing/0001193125-23-268401.md","text":"https://secwatch.observer/filing/0001193125-23-268401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/d538206d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:04:12.234393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2611d5d524","claim":"Jasper Bos resigned as Chief Executive Officer at Forbion European Acquisition Corp..","evidence_excerpt":"On October 31, 2023, each of (i) Mr. Jasper Bos and (ii) Mr. Cyril Lesser resigned as Chief Executive Officer and Chief Financial Officer, respectively, of the Company, effective on October 31, 2023 upon the completion of the Business Combination.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"5a83957d66","claim":"Cyril Lesser resigned as Chief Financial Officer at Forbion European Acquisition Corp..","evidence_excerpt":"On October 31, 2023, each of (i) Mr. Jasper Bos and (ii) Mr. Cyril Lesser resigned as Chief Executive Officer and Chief Financial Officer, respectively, of the Company, effective on October 31, 2023 upon the completion of the Business Combination.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"6faa5f81c4","claim":"Ton Logtenberg resigned as member of the board of directors at Forbion European Acquisition Corp..","evidence_excerpt":"On October 31, 2023, each of (i) Mr. Sander Slootweg, (ii) Mr. Philip Astley-Sparke, (iii) Ms Hilde Steineger and (iv) Mr. Ton Logtenberg resigned as members of the board of directors of the Company, effective on October 31, 2023 upon the completion of the Business Combination.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the board of directors"}],"fact_type":"executive_change"},{"claim_id":"a8026105c3","claim":"Philip Astley-Sparke resigned as member of the board of directors at Forbion European Acquisition Corp..","evidence_excerpt":"On October 31, 2023, each of (i) Mr. Sander Slootweg, (ii) Mr. Philip Astley-Sparke, (iii) Ms Hilde Steineger and (iv) Mr. Ton Logtenberg resigned as members of the board of directors of the Company, effective on October 31, 2023 upon the completion of the Business Combination.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the board of directors"}],"fact_type":"executive_change"},{"claim_id":"c6a6a4f75f","claim":"Sander Slootweg resigned as member of the board of directors at Forbion European Acquisition Corp..","evidence_excerpt":"On October 31, 2023, each of (i) Mr. Sander Slootweg, (ii) Mr. Philip Astley-Sparke, (iii) Ms Hilde Steineger and (iv) Mr. Ton Logtenberg resigned as members of the board of directors of the Company, effective on October 31, 2023 upon the completion of the Business Combination.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the board of directors"}],"fact_type":"executive_change"},{"claim_id":"dcaab157b3","claim":"Hilde Steineger resigned as member of the board of directors at Forbion European Acquisition Corp..","evidence_excerpt":"On October 31, 2023, each of (i) Mr. Sander Slootweg, (ii) Mr. Philip Astley-Sparke, (iii) Ms Hilde Steineger and (iv) Mr. Ton Logtenberg resigned as members of the board of directors of the Company, effective on October 31, 2023 upon the completion of the Business Combination.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the board of directors"}],"fact_type":"executive_change"},{"claim_id":"e63c8441c1","claim":"Wouter Joustra resigned as member of the board of directors at Forbion European Acquisition Corp..","evidence_excerpt":"On October 31, 2023, Mr. Wouter Joustra resigned as member of the board of directors of the Company, effective upon the completion of the liquidation of the Company under Cayman law, which is expected to take place on or before January 31, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the board of directors"}],"fact_type":"executive_change"},{"claim_id":"2aafed4555213009515016cd8a02a983b009dd94","claim":"Forbion European Acquisition Corp. underwent a change of control involving enGene Holdings Inc. (New enGene) (closed 2023-10-31).","evidence_excerpt":"On October 31, 2023 (the “Closing Date”), Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation (“FEAC” or the “Company”), enGene, Inc., a corporation incorporated under the laws of Canada (“enGene”), and enGene Holdings Inc. (New enGene”) consummated the previously announced business combination (the “Business Combination”) pursuant to the Business Combination Agreement","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"enGene Holdings Inc. (New enGene)"},{"label":"Closing","value":"2023-10-31"}],"fact_type":"ma_transaction"},{"claim_id":"10532cae309be6325486448859416f9d14c5b49e","claim":"Forbion European Acquisition Corp. entered into Registration Rights Agreement with New enGene, Sponsor Holders, enGene Holders valued at Customary registration rights granted to Sponsor Holders and enGene Holders (effective 2023-10-30).","evidence_excerpt":"On the Closing Date, New enGene, FEAC, the Sponsor Holders (as defined in the Registration Rights Agreement) and the enGene Holders (as defined in the Registration Rights Agreement) entered into a registration rights agreement (the “Registration Rights Agreement”), pursuant to which, among other things, New enGene granted the Sponsor Holders and the enGene Holders certain customary registration rights with respect to their respective Equity Securities (as defined in the Registration Rights Agreement) of New enGene, in each case, on the terms and subject to the conditions described therein.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"New enGene, Sponsor Holders, enGene Holders"},{"label":"Value","value":"Customary registration rights granted to Sponsor Holders and enGene Holders"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"},{"claim_id":"1878436955ddee416db65eefc7a9e1f789b7c7dc","claim":"Forbion European Acquisition Corp. terminated Administrative Services Agreement with Sponsor valued at Agreement terminated; Sponsor provided office space, secretarial and administrative services for up (effective 2023-10-30).","evidence_excerpt":"and (ii) the Administrative Services Agreement, dated as of December 9, 2021, between the Company and the Sponsor, pursuant to which the Sponsor provided the Company with office space, secretarial and administrative services for up to $10,000 per month.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Counterparty","value":"Sponsor"},{"label":"Value","value":"Agreement terminated; Sponsor provided office space, secretarial and administrative services for up"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"},{"claim_id":"85331e3377f8316b319fe9edc7a2263b0b2caf63","claim":"Forbion European Acquisition Corp. entered into Warrant Assignment, Assumption and Amendment Agreement with FEAC, enGene, New enGene, Continental Stock Transfer & Trust Company valued at New enGene assumed FEAC warrants to purchase FEAC Class A Shares at $11.50 per share (effective 2023-10-30).","evidence_excerpt":"On October 30, 2023, FEAC, enGene, New enGene and Continental Stock Transfer & Trust Company, a New York corporation (“Continental”), entered into that certain Warrant Assignment, Assumption and Amendment Agreement (the “Warrant Assumption Agreement”) pursuant to which New enGene assumed the warrants of FEAC to purchase one FEAC Class A Share at an exercise price of $11.50 per share, subject to adjustment (the “FEAC Warrants,” and as so assumed, “New enGene Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"FEAC, enGene, New enGene, Continental Stock Transfer & Trust Company"},{"label":"Value","value":"New enGene assumed FEAC warrants to purchase FEAC Class A Shares at $11.50 per share"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"},{"claim_id":"ed8539a69743c7056b7a3bce8845e404ed3b3785","claim":"Forbion European Acquisition Corp. terminated Investment Management Trust Agreement with Continental Stock Transfer & Trust Company valued at Agreement terminated in connection with consummation of Business Combination (effective 2023-10-30).","evidence_excerpt":"in connection with the consummation of the Business Combination, the following material agreements of the Company terminated in accordance with their terms: (i) the Investment Management Trust Agreement, dated as of December 9, 2021, by and between the Company and Continental, pursuant to which Continental invested the proceeds of the Company’s initial public offering in a trust account;","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1874495/000119312523268401/0001193125-23-268401-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Counterparty","value":"Continental Stock Transfer & Trust Company"},{"label":"Value","value":"Agreement terminated in connection with consummation of Business Combination"},{"label":"Effective","value":"2023-10-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}